- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03162640
Impulsivity and Time Perception
August 24, 2023 updated by: University Hospital, Strasbourg, France
Link Between Impulsivity and Time Anticipation
Cannabis smokers having begun prematurely their consumption (before 16 years) present a persistent impulsivity much later after have stopped their consumptions.
The literature highlights that the impulsivity promotes the passage towards a compulsive consumption, and the loss of control.
To explain this phenomenon, some authors hypothesized that impulsivity would lead the subjects to overestimate the duration of events and to choose immediate rewards than preferred but delayed rewards.
This hypothesis questions the role of the temporal anticipation in the impulsive choices.
In a first hypothesis, the temporal impulsivity could be an endogenous deficit bound to the reward, and would be responsible for disorders of the temporal anticipation.
In this case, the disorders should be observed especially when the subject anticipates a reward.
Alternately, a disorder of the temporal anticipation could provoke impulsivity, and in this case, would be present with or without reward.
To separate these hypotheses, we propose to test the capacities of temporal anticipation of non-smokers and early smokers of cannabis by means of a behavioral task " Hazard function task ", which allow to measure the capacity of a subject to anticipate the apparition of an event on the basis of a temporal cue.
The neuronal correlates will be measured by a recording EEG of the wave ' CNV ' (fix a quota for denial of variation) which reflects the temporal accumulation and the processes of anticipation.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
38
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Laurence LALANNE-TONGIO, MD
- Phone Number: +33 3.88.11.51.35
- Email: laurence.lalanne@chru-strasbourg.fr
Study Contact Backup
- Name: Anne GIERSCH, MD
- Phone Number: +33 3.88.11.64.71
- Email: giersch@unistra.fr
Study Locations
-
-
Alsace
-
Strasbourg, Alsace, France, 67091
- Les Hôpitaux Universitaires de Strasbourg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Cannabis use Versus Non-smokers
Description
Inclusion Criteria:
- Healthy volunteers Man or woman of age between 18 and 50 years-old
- Absence of consumption of cannabis and tobacco for 1 year and absence of substance use disorder in history
- Matching in age and sex to the group consumers of cannabis
- Early consumers of cannabis (at the beginning of the consumptions before 16 years)
- Man or woman of age between 18 and 50 years old
- Statement of more than three consumptions a day of cannabis for at least one year and consumption of cannabis having begun before the age of 16 years.
- Urinary analysis is positive for the presence of cannabis
- Positive auto-questionnaire CAST: 2 positive answers to CAST questionnaire
- Hospitalized or not
Exclusion Criteria:
Presence or history of a severe and invalidating somatic pathology (neurological, cardiovascular, lung, metabolic, renal, hepatic, gastro-intestinal)
- History of cranial trauma with loss of consciousness.
- substance use disorder except the substance tested in the protocol (cannabis).
- Invalidating sensory disorders in particular visual: glaucoma, any retinal pathology. Visual acuteness 0.8
- History of general anesthesia in the previous 3 months the study
- Any evolutionary neurological or psychiatric pathology
- Subject under guardianship
- pregnancy
- Feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
P
for cannabis
|
C
for the control group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure the capacities of the subjects to anticipate the apparition of the target
Time Frame: 8 days after inclusion in the study
|
on the basis of a temporal cue presented before the target, and give the response as quickly as possible after the presentation of a rewarding versus not rewarding target.
|
8 days after inclusion in the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Laurence LALANNE-TONGIO, MD, Hôpitaux Universitaires de Strasbourg
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 5, 2017
Primary Completion (Actual)
March 12, 2020
Study Completion (Actual)
March 12, 2020
Study Registration Dates
First Submitted
May 19, 2017
First Submitted That Met QC Criteria
May 19, 2017
First Posted (Actual)
May 22, 2017
Study Record Updates
Last Update Posted (Actual)
August 29, 2023
Last Update Submitted That Met QC Criteria
August 24, 2023
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6526
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cannabis Use
-
Centre hospitalier de l'Université de Montréal...RecruitingCannabis | Cannabis Dependence | Cannabis Use | Cannabis Smoking | Cannabis Use, UnspecifiedCanada
-
The University of Tennessee, KnoxvilleColorado State UniversityActive, not recruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Elias DakwarRecruitingAddiction | Cannabis Dependence | Cannabis Use | Substance Abuse | Cannabis Abuse | Cannabis Use DisorderUnited States
-
Monash UniversityTurning PointCompletedCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereAustralia
-
Oregon Research InstituteCompletedCannabis Use Disorder, Mild | Cannabis Use Disorder, ModerateUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); Food and Drug Administration (FDA)Not yet recruitingTobacco Use | Cannabis | Cannabis Use | Vaping | THC | Cannabis SmokingUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingBipolar Disorder | Cannabis Use | Bipolar I Disorder | Cannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe | Bipolar II Disorder | Schizoaffective Disorder, Bipolar TypeUnited States
-
Hartford HospitalYale UniversityNot yet recruitingMarijuana Use | Cannabis Use | Cannabis Intoxication
-
McMaster UniversityCenter for Medicinal Cannabis ResearchNot yet recruitingCannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe